1. Home
  2. ALT vs MMD Comparison

ALT vs MMD Comparison

Compare ALT & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • MMD
  • Stock Information
  • Founded
  • ALT 1997
  • MMD 2012
  • Country
  • ALT United States
  • MMD United States
  • Employees
  • ALT N/A
  • MMD N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • MMD Investment Managers
  • Sector
  • ALT Health Care
  • MMD Finance
  • Exchange
  • ALT Nasdaq
  • MMD Nasdaq
  • Market Cap
  • ALT 327.4M
  • MMD 274.9M
  • IPO Year
  • ALT N/A
  • MMD N/A
  • Fundamental
  • Price
  • ALT $3.57
  • MMD $15.43
  • Analyst Decision
  • ALT Strong Buy
  • MMD
  • Analyst Count
  • ALT 6
  • MMD 0
  • Target Price
  • ALT $17.40
  • MMD N/A
  • AVG Volume (30 Days)
  • ALT 2.3M
  • MMD 74.7K
  • Earning Date
  • ALT 11-11-2025
  • MMD 01-01-0001
  • Dividend Yield
  • ALT N/A
  • MMD 4.88%
  • EPS Growth
  • ALT N/A
  • MMD N/A
  • EPS
  • ALT N/A
  • MMD N/A
  • Revenue
  • ALT $20,000.00
  • MMD N/A
  • Revenue This Year
  • ALT N/A
  • MMD N/A
  • Revenue Next Year
  • ALT $761,880.20
  • MMD N/A
  • P/E Ratio
  • ALT N/A
  • MMD N/A
  • Revenue Growth
  • ALT N/A
  • MMD N/A
  • 52 Week Low
  • ALT $2.90
  • MMD $14.30
  • 52 Week High
  • ALT $11.16
  • MMD $17.67
  • Technical
  • Relative Strength Index (RSI)
  • ALT 44.06
  • MMD 75.57
  • Support Level
  • ALT $3.54
  • MMD $15.25
  • Resistance Level
  • ALT $3.72
  • MMD $14.66
  • Average True Range (ATR)
  • ALT 0.16
  • MMD 0.14
  • MACD
  • ALT 0.01
  • MMD 0.07
  • Stochastic Oscillator
  • ALT 10.94
  • MMD 93.75

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund

NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.

Share on Social Networks: